Stock listing

OTC:ARYX Aryx Therapeutics Inc Stock

Follow Aryx Therapeutics Inc into a list and get an email when it puts out news.

Aryx Therapeutics Inc logo
Ticker
OTC:ARYX
Asset type
Stock
Exchange
OTC
Currency
USD

Events

QuarterResults
Quarter to Sep 30, 2024Nov 18, 2024
Quarter to Jun 30, 2024Aug 12, 2024
Quarter to Mar 31, 2024May 16, 2024
Quarter to Dec 31, 2023Mar 25, 2024
Quarter to Sep 30, 2023Nov 13, 2023
Quarter to Jun 30, 2023Aug 14, 2023
Quarter to Mar 31, 2023May 11, 2023
Quarter to Dec 31, 2022Mar 27, 2023
Quarter to Sep 30, 2022Nov 14, 2022
Quarter to Jun 30, 2022Aug 15, 2022
All 16 quarters
QuarterResults
Quarter to Mar 31, 2022May 12, 2022
Quarter to Dec 31, 2021Mar 28, 2022
Quarter to Sep 30, 2021Nov 15, 2021
Quarter to Jun 30, 2021Aug 16, 2021
Quarter to Mar 31, 2021May 13, 2021
Quarter to Dec 31, 2020Mar 29, 2021

Open Events

Financials

Annual, in USD

Income statement

LineFY2009FY2008FY2007FY2006FY2005FY2004FY2003
Revenue019.7M4.16M4.74M
Cost of revenue0232.0K262.0K2.12M27.4M
Gross profit019.5M3.90M2.62M
Research and development21.0M40.1M25.0M24.0M22.5M10.7M
Selling, general and administrative10.2M10.1M7.70M6.94M
Operating income-31.2M-30.4M-28.8M-28.3M-28.2M-20.8M-14.1M
Depreciation and amortization1.08M1.46M1.24M920.0K982.0K
EBITDA-30.2M-29.0M-27.6M-27.4M-27.2M
Interest expense2.01M1.93M1.35M1.32M671.0K58.0K
Income before tax-33.2M-31.2M-27.6M-27.3M
Income tax849.0K801.0K-1.24M-960.0K-205.0K20.8M14.0M
Net income-33.2M-31.2M-27.6M-27.3M-28.0M-20.8M-14.0M
Earnings per share, basic-1.21-1.65-2.93-26.84-30.73-24.27-16.67

Balance sheet

LineFY2009FY2008FY2007FY2006FY2005FY2004FY2003
Cash and equivalents7.41M36.0M55.5M18.7M12.5M
Short-term investments353.0K8.59M7.64M31.6M13.9M
Receivables45.0K
Inventory0000
Current assets8.81M45.9M64.9M51.4M27.7M
Property, plant and equipment2.26M3.20M3.65M4.17M4.14M
Goodwill0000
Total assets12.4M51.1M69.6M56.8M33.3M8.85M
Accounts payable685.0K2.45M1.37M691.0K656.0K
Current liabilities8.68M11.0M13.5M11.5M7.75M
Long-term debt5.28M10.2M3.44M6.68M8.92M
Total debt11.8M14.7M6.98M9.88M11.2M
Total liabilities15.3M23.7M34.3M150.5M100.4M
Shareholders' equity-2.92M27.4M35.3M-93.7M-67.1M-18.9M
Shares outstanding27.4M19.0M9.41M1.02M910.0K858.0K838.0K

Cash flow

LineFY2009FY2008FY2007FY2006FY2005
Cash from operations-35.0M-45.2M-27.7M-4.21M-22.4M
Capital spending-141.0K-644.0K-499.0K-962.0K-3.85M
Free cash flow-35.1M-45.9M-28.2M-5.17M-26.3M
Cash from investing8.41M-2.41M23.4M-18.5M9.53M
Cash from financing-2.04M28.2M41.2M28.9M11.2M
Dividends paid0000
Share buybacks-92.0K000
Change in cash-28.6M-19.5M36.8M6.21M-1.73M

Open Financials

Cap table

Built by 6ix from Aryx Therapeutics Inc’s releases

Common shares
33,461,975
Fully diluted
33,461,975

Fully diluted

LineShares
Common shares33,461,975

Share count over time

CountShares
Nov 22, 202633,461,975

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Lars G. Ekman
Other companies: Prothena Corporation plc (Chair Emeritus · Since at least Dec 20, 2012); Ultragenyx Pharmaceutical Inc. (Director · Mar 17, 2016 – Jun 24, 2022 · Past); Spark Therapeutics Inc (Director · Jan 29, 2015 – Dec 17, 2019 · Past); Ocera Therapeutics Inc (Director · Jul 15, 2013 – Jun 11, 2014 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Jun 27, 2022 · Past); InterMune Inc (Director · May 10, 2010 – Sep 29, 2014 · Past)
Director · Apr 30, 2010 – Apr 30, 2010 · Past

Open People

Log in to ask 6ix AI your own questions about Aryx Therapeutics Inc.